SynthesisObesity surgery2026
Effect of Metabolic Bariatric Surgery on Cardiovascular Outcomes in People with Obesity and Pre-existing Cardiovascular Disease: A Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic bariatric surgery (MBS) effectively lowers the risk of cardiovascular (CV) events in individuals with obesity, however, its application in those with pre-existing CV disease has been limited due to concerns about perioperative outcomes.
objectiveThis study evaluates the effectiveness and safety of bariatric surgery in reducing CV risk in people with pre-existing CV disease.
methodsWe carried out an extensive search on PubMed, Google Scholar, Science Direct, and Clinicaltrial.gov from their inception until February 2025. Key outcomes included reductions in all-cause mortality (ACM), major adverse CV events (MACE), myocardial infarction (MI), and cerebrovascular events in people with and without prior CV disease undergoing bariatric surgery. Data were combined using a random-effects model and displayed as hazard ratios (HR) along with 95% confidence intervals (CI).
resultsThree studies (n = 3,888) were included, with 1,523 patients getting Roux-en-Y gastric bypass and 442 receiving sleeve gastrectomy. Median age ranged from 52 to 56 years. Metabolic bariatric surgery was associated with a significant reduction in ACM (HR = 0.48, 95% CI: 0.38 to 0.61, p < 0.01) and MACE (HR = 0.55, 95% CI: 0.45 to 0.67, p < 0.01). However, no significant reduction was observed for MI (HR = 0.53, 95% CI: 0.24 to 1.18, p = 0.12) or cerebrovascular events (HR = 0.99, 95% CI: 0.64 to 1.54, p = 0.96).
conclusionMetabolic bariatric surgery is associated with significantly lower ACM and MACE in people with obesity and prevalent CV disease. These results highlight the necessity for additional extensive trials to validate advantages in high-risk groups, specifically older individuals and those who have experienced prior MI or heart failure.
Indexed as
Identifiers
41944992What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.